GUILLERMO GARCIA-MANERO to Primary Myelofibrosis
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Primary Myelofibrosis.
Connection Strength
1.155
-
Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.
Score: 0.122
-
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica. 2021 11 01; 106(11):2853-2858.
Score: 0.116
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
Score: 0.114
-
Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol. 2021 Dec; 100(12):2957-2960.
Score: 0.114
-
Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999 Feb; 60(2):130-5.
Score: 0.096
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
Score: 0.093
-
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018 06; 42(6):799-806.
Score: 0.091
-
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res. 2016 09; 48:1-5.
Score: 0.080
-
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30.
Score: 0.067
-
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013 Oct; 92(10):1335-43.
Score: 0.064
-
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.
Score: 0.051
-
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
Score: 0.050
-
Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84.
Score: 0.040
-
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
Score: 0.038
-
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70.
Score: 0.011
-
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003 Jun 01; 97(11):2760-6.
Score: 0.008